Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? - Heart Failure Reviews
Source : https://link.springer.com/article/10.1007/s10741-023-10315-4
Heart failure (HF) with preserved ejection fraction (HFpEF) causes a progressive limitation of functional capacity, poor quality of life (QoL) and increased mortality, yet unlike HF with reduced ejection fraction...
Conclusions/Relevance: Available evidence on CCM in HFpEF is still preliminary, but improvements in terms of symptoms and QoL have been observed. Future large, dedicated, prospective studies are needed to evaluate the safety and efficacy of this therapy in patients with HFpEF.
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs
Source : https://www.sciencedirect.com/science/article/abs/pii/S2213177923001853?via=ihub
Available online 17 May 2023 Author links open overlay panel, b c , , , , a e , , , , , g h , , , , l...
Conclusions: Utilization rates of SGLT2 inhibitors are low in patients with ASCVD, HF, and T2DM, with high residual facility-level variation. These findings suggest opportunities to optimize SGLT2 inhibitor use to prevent future adverse cardiovascular events.
Shockwave lithotripsy of calcific stenosis of the distal abdominal aorta to facilitate transcatheter aortic valve replacement
Source : https://www.sciencedirect.com/science/article/abs/pii/S1553838923001616?via=ihub
The transfemoral approach for transcatheter aortic valve replacement (TAVR) is superior to alternative access strategies. Only transfemoral access has...
Relevance: We applied intravascular lithotripsy (IVL) to the distal abdominal aorta to achieve necessary luminal gain facilitating bioprosthetic aortic valve deployment.
Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial - Trials
Source : https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07332-x
Background Heart failure with reduced ejection fraction (HFrEF) is associated with sleep dyspnea (SDB), which plays an adverse role in the pathophysiology of the condition. SDB management in HFrEF, however,...
Conclusion: In summary, our RCT will provide data for analyses of the relationship between OSA and dapagliflozin, which may be a potential treatment for sleep apnea.
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Source : https://www.sciencedirect.com/science/article/pii/S0735109723050805?via=ihub
Empagliflozin reduces the risk of major heart failure outcomes in heart failure with reduced or preserved ejection fraction. The goal of this study was to evaluate the effect of empagliflozin...
Conclusions: The benefit of empagliflozin on major heart failure events was not influenced by KDIGO categories. The magnitude of the renal effects of the drug depended on the approach used to calculate eGFR slopes.
